Key Takeaways:
Entrada Therapeutics (NASDAQ: TRDA) shares plunged more than 57% after initial data for its Duchenne muscular dystrophy drug showed it missed a key efficacy goal, raising doubts about its competitiveness despite the company highlighting positive safety and functional signals.
"While ENTR-601-44 prompted modest increases in dystrophin levels, the drug offered a significant 0.08-point improvement from baseline in mean change in time to rise (TTR) scores," William Blair analysts noted, capturing the mixed nature of the results that ultimately disappointed investors.
The Phase I/II study showed ENTR-601-44 produced a mean dystrophin increase of just 2.36%, well below the 10% change from baseline that analysts and investors had anticipated. The stock fell from $16.03 to $6.85 on the news. However, the company reported no serious adverse events and a statistically significant improvement in time-to-rise velocity, a key measure of motor function.
The results place Entrada at a disadvantage to Novartis-owned Avidity Biosciences, whose rival drug del-zota recently demonstrated a 25% increase in dystrophin production. Entrada must now prove that a higher 12 mg/kg dose in its next cohort, with data expected by the end of 2026, can remain viable in the exon 44 skipping DMD market.
Entrada's management framed the initial data from the ELEVATE-44-201 trial as encouraging, pointing to the favorable safety profile and the functional improvements observed even at the lowest dose of 6 mg/kg. All treatment-emergent adverse events were mild to moderate, and no participants discontinued the study.
The company highlighted a statistically significant improvement in time-to-rise velocity, a measure of motor function, which it said was 3.5 times higher than the minimal clinically important difference. However, investors focused on the primary efficacy endpoint: dystrophin production. The 2.36% increase fell dramatically short of the whisper number of 10% and pales in comparison to the 25% increase reported by Avidity for its competing drug, del-zota.
Entrada executives explained that plasma exposure of the drug in pediatric patients was about 50% lower than seen in healthy adults, potentially impacting the drug's concentration in muscle tissue and thus limiting dystrophin production. The company said it has updated its modeling and expects "double-digit dystrophin levels" from the trial's second cohort, which is receiving a 12 mg/kg dose.
Data from this higher-dose cohort, along with the open-label extension for the first cohort, are not expected until the end of 2026. With a cash runway into the third quarter of 2027, Entrada has the funds to see the next readout, but now faces a much higher bar to prove its drug can compete effectively. The significant stock drop reflects investor skepticism that a simple dose escalation can bridge the large efficacy gap with Avidity's candidate.
This article is for informational purposes only and does not constitute investment advice.
